PI-RADS v2与adjusted-PSAD联合运用对前列腺高级别癌的诊断价值分析

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the value of combing Prostate Imaging Reporting and Data System(PI-RADS) scores with adjusted-Prostate Specific Antigen Density(adjusted-PSAD) in diagnosing high-grade prostate cancer(HGPCa). Methods: Magnetic resonance imaging data of 168 patients from January 2013 to August 2016 were analyzed retrospectively. According to the pathological results, the cases were divided into two groups, one was high-grade group(52 cases), the other was non-high-grade group. The concordance of PI-RADS v2 scores in two independent observers was tested by Kappa statistic. The performance of PI-RADS v2 alone and PI-RADS v2 combined with other parameters in the diagnosis of high-grade prostate cancer were assessed. Futhermore, Spearman correlation analysis was used to explore the relationship between each parameter with Gleason score. Results: The concordance of PI-RADS v2 scores in two independent observers was moderate(Kappa=0.478). The ROC curve analysis showed that the area under the curve(AUC) of PI-RADS v2 combined with adjusted-PSAD was larger(P<0.05), and AUC, sensitivity, specificity, PPV, NPV were 91%, 85%, 87%, 75%, 93%, respectively. Furthermore, PI-RADS v2 score showed a significant positive correlation with Gleason scores of HGPCa(r=0.423, P=0.001). Conclusions: PI-RADS v2 combined with adjusted-PSAD demonstrated good accuracy in detecting HGPCa, and PI-RADS v2 score can be served for evaluating aggressiveness of HGPCa non-invasively.

Key words： Prostatic neoplasms Magnetic resonance imaging

Received: 13 March 2017

PACS:	Ｒ737.25
	Ｒ445.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Lin
	NIU Xiang-ke
	CHEN Zhi-fan
	PU Bing-jie
	PENG Tao

Cite this article:

LI Lin,NIU Xiang-ke,CHEN Zhi-fan, et al. The value of combining PI-RADS v2 with adjusted-PSAD in diagnosis of high-grade prostate cancer[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2018, 29(1): 42-45.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2018/V29/I1/42

[1]Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh A, et al. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide[J]. Prostate Int, 2016, 4: 118-124.
[2]Woodhams S, Greenwell T. The clinical utility of measuring free-to-total prostate-specific antigen(PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer[J]. Br J Urol, 1998, 82: 933.
[3]Park SY, Jung DC, Oh YT, et al. Prostate Cancer: PI-RADS Version 2 Helps Preoperatively Predict Clinically Significant Cancers[J]. Radiology, 2016, 280(1): 108-116.
[4]Muller BG, Shih JH, Sankineni S, et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging[J]. Radiology, 2015, 277(3): 741-750.
[5]Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology(ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System[J]. Am J Surg Pathol, 2016, 40(2): 244-252.
[6]Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications[J]. Diagn Pathol, 2016, 11(1): 1-8.
[7]Muller BG, Shih JH, Sankineni S, et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging[J]. Radiology, 2015, 277(3): 741-750.
[8]Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia[J]. J Urol, 1990, 143(4): 747-752.
[9]Benson ML, Whang IS, Pantuck A, et al. Prostate specific antigen density a means of distinguishing benign prostatic hypertrophy and prostate cancer[J]. J Urol, 1992, 147: 815.
[10]Paterson NR, Lavallée LT, Nguyen LN, et al. Prostate volume estimations using magnetic resonance imaging and transrectal ultrasound compared to radical prostatectomy specimens[J]. Can Urol Assoc J, 2016, 10(7-8): 264.
[11]Kasel-Seibert M, Lehmann T, Aschenbach R, et al. Assessment of PI-RADS v2 for the Detection of Prostate Cancer[J]. Eur J Radiol, 2016, 85(4): 726-731.
[12]Zhao C, Gao G, Fang D, et al. The efficiency of multiparametric magnetic resonance imaging(mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer[J]. Clin Imaging, 2016, 40(5): 885-888.
[13]Lin WC, Westphalen AC, Silva GE, et al. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer[J]. Abdom Radiol, 2016, 41(11): 1-9.
[14]Chung MP, Margolis D, Mesko S, et al. Correlation of quantitative diffusion-weighted and dynamic contrast-enhanced MRI parameters with prognostic factors in prostate cancer[J]. J Med Imaging Radiat Oncol, 2014, 58(5): 588.
[15]Inés BP, Lía BG, Javier SF. Association between gleason score, psa level, PSAD and prostate volume, in a series of patients with prostate adenocarcinoma[J]. Revista Ciencias Biomédicas, 2012, 3(1): 58-68.